Podcast Index
Explora podcasts por categoría, abre episodios recientes y descarga audio para escucharlo sin conexión.
BioCentury This Week
BioCentury
CME in Minutes: Education in Gastroenterology
Answers in CME
The 40k Lorecast
Warhammmer 40k
East Rosebud Studios Podcast
FHW
Making Coffee with Lucia Solis
Lucia
Aha! Zehn Minuten Alltags-Wissen
WELT
Growing Up Podcast
Andy Perry and Kate Perry
For Kidneys Sake
North West London Kidney Care
Artificial Intelligence Masterclass
AI Masterclass
Quazi Johir
Quazi Johir
The Science of Everything Podcast
James Fodor
Investigate Earth Conspiracy Podcast
Do Without Fear Media
BBC Gardeners’ World Magazine Podcast
Immediate Media
Allt du velat veta
Acast - Fritte Fritzson
Handelsblatt Green & Energy - Der Podcast rund um Nachhaltigkeit, Klima und Energiewende
Kathrin Witsch, Catiana Krapp, Kevin Knitterscheidt, Michael Scheppe
Dietetics with Dana
Dana J. Fryer, MS, RDN, CNSC
UFO Chronicles Podcast
Nik Hunter
Radiowissen
Bayerischer Rundfunk
Permaculture P.I.M.P.cast
Permaculture P.I.M.P.cast
The Fossil Files
Robert Sansom and Susannah Maidment
ReddX Reddit Reads
ReddX
Der Pragmaticus Podcast
Der Pragmaticus
Geek News Central Podcast
Todd Cochrane
The Lookout Podcast
The Lookout Podcast
Learning & Living STEMM in Connecticut
The Connecticut Academy of Science and Engineering
Authentic Biochemistry
Dr Daniel J. Guerra
The Brohio Podcast
Aliens, Conspiracy Theories, Paranormal, Famous Murders, Cryptozoology, Strange Occurrences, Monsters, UFOs, True Crime, Demons, Occult, Urban Legends, Comedy
The Grave Talks | Haunted, Paranormal & Supernatural
Ghost Stores, Haunted, Paranormal & Supernatural Stories
The Plodcast
Our Media
Real Ghost Stories Online
Real Ghost Stories Online | Paranormal, Supernatural & Horror Radio
Energy vs Climate: How climate is changing our energy systems
Energy vs Climate | Produced by Amit Tandon & Bespoke Podcasts
The Dermalorian Podcast
Dermatology Education Foundation
The Science in The Fiction
Marty Kurylowicz and Holly Carson
Der KI-Podcast
ARD
NEU DENKEN
Mission Wertvoll
Contacto Siniestro Podcast
Siniestro Producciones
Curiuss
Alan Zamboni
Ciencia
BioCentury
New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts re...
AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeo...
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $...
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.From AI to NAMs to starting a Phase I trial in the U.S., BioCentury’s 3rd Grand Round...
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdi...
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data...
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to t...
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin disc...
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer I...
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the lates...
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCe...
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make ...
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-i...
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASD...
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, ...
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentur...
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum from Asia, in particular China, has added a f...
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioCentury’s Paul Bonanos assesses last week’s deals by Merck, which is lay...
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how the company has built...
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on NASDAQ — but will geopolitical tensions and war in the Middle East scut...
Completa el formulario de abajo. Asegúrate de seleccionar tanto País como Géneros.
Envíanos un mensaje abajo. Te responderemos en un plazo de 24 horas.